Orca Wealth Management LLC Acquires New Position in Danaher Corporation $DHR

Key Points

• Orca Wealth Management LLC has acquired a new stake in Danaher Corporation, purchasing 2,478 shares valued at approximately $490,000 in the second quarter.
• Several institutional investors, including OLD National Bancorp and Tandem Investment Partners, have also increased their holdings in Danaher during the same period, highlighting growing investor confidence.
• Danaher recently announced a quarterly dividend of $0.32 per share, representing an annual yield of 0.6%, with a payout ratio of 27.23%.

Orca Wealth Management LLC acquired a new stake in shares of Danaher Corporation (NYSE:DHR - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,478 shares of the conglomerate's stock, valued at approximately $490,000.

A number of other institutional investors have also modified their holdings of the business. OLD National Bancorp IN boosted its stake in Danaher by 11.2% during the 2nd quarter. OLD National Bancorp IN now owns 75,597 shares of the conglomerate's stock valued at $14,933,000 after purchasing an additional 7,642 shares during the period. Tandem Investment Partners LLC boosted its stake in Danaher by 12.5% during the 2nd quarter. Tandem Investment Partners LLC now owns 3,460 shares of the conglomerate's stock valued at $683,000 after purchasing an additional 385 shares during the period. AMF Tjanstepension AB boosted its stake in Danaher by 117.0% during the 2nd quarter. AMF Tjanstepension AB now owns 373,173 shares of the conglomerate's stock valued at $73,733,000 after purchasing an additional 201,242 shares during the period. Sava Infond d.o.o. boosted its stake in Danaher by 28.0% during the 2nd quarter. Sava Infond d.o.o. now owns 5,300 shares of the conglomerate's stock valued at $1,047,000 after purchasing an additional 1,160 shares during the period. Finally, 111 Capital boosted its stake in Danaher by 81.3% during the 2nd quarter. 111 Capital now owns 5,908 shares of the conglomerate's stock valued at $1,167,000 after purchasing an additional 2,649 shares during the period. Institutional investors own 79.05% of the company's stock.

Insider Buying and Selling

In related news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

DHR has been the subject of a number of analyst reports. Weiss Ratings reissued a "hold (c-)" rating on shares of Danaher in a research note on Saturday, September 27th. Royal Bank Of Canada set a $241.00 target price on shares of Danaher in a research note on Tuesday, September 2nd. Guggenheim reissued a "buy" rating and set a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. Robert W. Baird upped their price target on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research note on Friday, July 18th. Finally, Evercore ISI reduced their price target on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Seventeen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $245.91.

Danaher Trading Up 2.2%

Shares of NYSE:DHR opened at $215.05 on Friday. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.41. The firm has a market cap of $153.98 billion, a P/E ratio of 45.75, a P/E/G ratio of 3.06 and a beta of 0.77. The company has a 50 day moving average of $200.19 and a 200-day moving average of $197.33. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same period in the prior year, the business earned $1.72 earnings per share. The business's quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher's dividend payout ratio is currently 27.23%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.